

**Press Release****Ajanta Pharma announces Rs. 356 cr. buyback  
of equity shares**

(Including tax on buy back of equity shares)

---

**Mumbai, 28<sup>th</sup> December 2021:** The Board of Directors of Ajanta Pharma Ltd. a specialty pharmaceutical formulation company, approved today buyback of up to 11,20,000 fully paid-up Equity Shares of face value of Rs. 2/- each by the Company at a price of Rs. 2,550/- per Equity Share payable in cash.

The total pay-out towards buyback of shares will be not exceeding Rs. 356 crores (equity shares buyback consideration not exceeding Rs. 286 crores + buyback tax not exceeding Rs. 70 crores) on a proportionate basis through the tender offer process.

This buyback represents 1.29% of the total number of equity shares of the company and 9.89% of the paid-up share capital and free reserves of the company as per the audited financial statements for the financial year ended on March 31, 2021.

Record date for the same has been fixed as 14th January 2022.

**About Ajanta Pharma Limited**

Ajanta Pharma is a speciality pharmaceutical formulation company having branded generic business in India and emerging markets, generic business in US and institution business in Africa. Many of company's products are 1<sup>st</sup> to market and are leading in their sub-therapeutic segments.

Company's state of the art R&D centres for formulation development and API are located at Mumbai. Company has 8 world class manufacturing facilities located in India and Mauritius.

For last 10 financial years, company has posted healthy performance with its Revenue from Operations growing at 17% CAGR and Net Profit at 27% CAGR.

For more details visit [www.ajantapharma.com](http://www.ajantapharma.com)

For regular updates follow us on twitter– [www.twitter.com/ajantapharmaltd](https://www.twitter.com/ajantapharmaltd)

**For specific queries, contact:**

Rajeev Agarwal Tel: +91 22 66061377 Email: [rajeev.agarwal@ajantapharma.com](mailto:rajeev.agarwal@ajantapharma.com)

Abhineet Kumar Tel: +91 22 66061814 Email: [abhineet.kumar@ajantapharma.com](mailto:abhineet.kumar@ajantapharma.com)

Reuters: AJPH.NS, Bloomberg: AJP:IN, NSE: AJANTPHARM, BSE: 532331  
Corporate Identity Number (CIN): L24230MH1979PLC022059

**Safe Harbour Statement**